The clinical alarm management market is estimated at USD 1.96B in 2025 and is expected to reach USD 4B by 2033, driven by mandatory alarm fatigue reduction mandates and accelerating adoption of AI-driven alarm filtering in ICU and step-down care settings. The single greatest structural risk is the persistent fragmentat Clinical alarm management encompasses the software platforms, middleware integrations, hardware adjuncts, and clinical workflow protocols that hospitals use to reduce alarm fatigue, improve alarm fidelity, and route actionable alerts to the right clinician at the right time.
Market Size (2025)
USD 1.96 Billion
Projected (2026–2033)
USD 4 Billion
CAGR
9.2%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Clinical Alarm Management Market is valued at USD 1.96 Billion and is projected to grow at a CAGR of 9.2% during 2026–2033. North America holds the largest regional share, while Asia Pacific is the fastest-growing market.
Study Period
2019–2033
Market Size (2025)
USD 1.96 Billion
CAGR (2026–2033)
9.2%
Largest Market
North America
Fastest Growing
Asia Pacific
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Clinical Alarm Management market valued at USD 1.96 Billion in 2025, projected to reach USD 4 Billion by 2033 at 9.2% CAGR
Key growth driver: Mandatory Joint Commission & CMS Alarm Safety Compliance (High, +9% CAGR impact)
North America holds the largest market share, while Asia Pacific is the fastest-growing region
AI Impact: Machine learning applications in clinical alarm management are materially more advanced than the broader healthcare AI narrative suggests. Discriminative models trained on institutional ECG archives — using convolutional neural networks to distinguish true arrhythmia from lead artifact, have demonstrated 40–80% reductions in non-actionable cardiac monitor alarms in peer-reviewed pilot studies at institutions including Johns Hopkins and UCSF.
15 leading companies profiled including GE HealthCare Technologies Inc., Philips Healthcare N.V., Medtronic plc and 12 more
Machine learning applications in clinical alarm management are materially more advanced than the broader healthcare AI narrative suggests. Discriminative models trained on institutional ECG archives — using convolutional neural networks to distinguish true arrhythmia from lead artifact, have demonstrated 40–80% reductions in non-actionable cardiac monitor alarms in peer-reviewed pilot studies at institutions including Johns Hopkins and UCSF. The FDA's March 2024 Predetermined Change Control Plan guidance creates a regulatory pathway for these adaptive models to retrain on new institutional data without requiring a supplemental 510(k) submission for each algorithm update, a development that substantially reduces the compliance overhead of deploying continuously learning alarm management AI. The practical implication: AI alarm platforms are now commercially viable in a way they were not before 2023, and the 13.8% CAGR we attribute to the AI/ML alarm filtering segment (Claritas model) reflects genuine commercial pull, not speculative projection.
The more nuanced AI opportunity sits in multimodal alarm correlation: combining physiologic waveform analysis with laboratory trend data, medication administration records, and nursing documentation to generate a composite alarm probability score that accounts for clinical context. Current rule-based alarm management platforms cannot integrate across these data domains without expensive custom EMR integration; AI models operating on FHIR R4 APIs can do so more efficiently. Connected pen-injector telemetry and continuous glucose monitor data streams, relevant given the hybrid closed-loop trials underway (NCT06962410, NCT06941675, nct:NCT06962410; nct:NCT06941675), represent a specific data type that current alarm management platforms struggle to integrate, creating a whitespace for AI middleware vendors with FHIR-native architectures.
One honest caveat on AI alarm management: algorithm generalizability remains a genuine clinical risk. Models trained on adult ICU populations at tertiary academic centers perform measurably worse when deployed in community hospital step-down units or pediatric settings. The FDA's expectation that manufacturers monitor and report post-deployment performance under the Real-World Performance (RWP) framework adds a surveillance obligation that smaller AI vendors may lack the infrastructure to fulfill. Regulators' growing focus on LLM and generative AI in healthcare, documented in the 880-citation paper on regulatory oversight of large language models (openalex:W4383346782), will extend to alarm management AI as these tools incorporate natural language interfaces and reasoning-based alarm justification. Vendors that invest in robust post-market surveillance infrastructure now will carry a durable regulatory advantage.
Clinical alarm management encompasses the software platforms, middleware integrations, hardware adjuncts, and clinical workflow protocols that hospitals use to reduce alarm fatigue, improve alarm fidelity, and route actionable alerts to the right clinician at the right time. The market sits at the intersection of patient monitoring hardware, dominated by GE Healthcare (FY2025 revenue USD 20.63B, edgar:GEHC-10K-2025), Medtronic (FY2025 revenue USD 33.54B, edgar:MDT-10K-2025), and Masimo (FY2026 revenue USD 1.53B following consumer segment restructuring, edgar:MASI-10K-2026), and a growing ecosystem of independent alarm orchestration software vendors. Our base case anchors the 2025 market at USD 1.96B (Claritas model), applying a blended 9.2% CAGR through 2033 derived from comparable healthcare IT infrastructure growth observed across enterprise clinical communications platforms and patient safety technology categories.
The demand-side case is largely regulatory in origin. The Joint Commission's National Patient Safety Goal NPSG.06.01.01, first mandated in 2014 and iteratively tightened, requires accredited hospitals to maintain formal alarm management programs with documented policies, staff education, and performance monitoring. CMS Conditions of Participation reinforce this through surveyor guidance that ties alarm-related sentinel events to reimbursement risk. These mandates have converted what was once an optional capital investment into a compliance-driven procurement, effectively creating a floor under demand irrespective of macro hospital capital budget cycles.
The contrarian read on this market: most sell-side analysts anchor growth to device unit volume and monitor refresh cycles. They are, in our view, mispricing the software layer. The real pricing power is accruing to alarm middleware vendors. Capsule Technologies, Bernoulli Health, and Connexall, that aggregate alarms from heterogeneous device ecosystems and apply clinical logic engines to filter, escalate, and document events. A large academic medical center running 400+ monitored beds easily generates 2.5 million alarms annually, of which peer-reviewed literature consistently shows 85–99% are non-actionable. The economic case for filtering software is unambiguous; the question is which vendor captures it. OEM-native alarm management bundles, offered as add-ons to proprietary monitoring suites, face integration disadvantage in mixed-vendor environments that describe the majority of U.S. and European hospital fleets.
Global health expenditure context is relevant for sizing the addressable population. World health spend per capita reached USD 1,317 in 2023 (wb:WLD-SH.XPD.CHEX.PC.CD-2023), with the U.S. at USD 13,473 (wb:USA-SH.XPD.CHEX.PC.CD-2023), the EU at USD 4,154 (wb:EUU-SH.XPD.CHEX.PC.CD-2023), Japan at USD 3,638 (wb:JPN-SH.XPD.CHEX.PC.CD-2023), China at USD 763 (wb:CHN-SH.XPD.CHEX.PC.CD-2023), and India at USD 85 (wb:IND-SH.XPD.CHEX.PC.CD-2023). The gradient from high- to low-spend markets is not simply a revenue stratification exercise; it maps directly onto the adoption timeline for enterprise alarm management platforms, which require a sufficient density of networked, EMR-integrated monitoring equipment to function as designed. China and India represent long-cycle opportunities, meaningful by 2028–2030, rather than near-term revenue contributors.
Alarm management is increasingly entangled with adjacent clinical decision support domains: remote patient monitoring, telemetry-as-a-service, and early warning scoring systems. The ongoing NCT06620653 Heart Failure Virtual Ward trial (start October 2024, National University of Ireland Galway) exemplifies how telemonitoring infrastructure generates alarm management requirements outside the physical hospital perimeter (nct:NCT06620653). Similarly, the BoraCare COPD remote monitoring study (NCT06523140, start November 2024) applies a proprietary early-detection score to generate clinician-facing alerts from wearable sensors, a direct analogue to in-hospital alarm management logic applied to outpatient chronic disease populations (nct:NCT06523140). These trials, while not alarm management studies per se, illustrate the convergence that is expanding the total addressable market beyond the ICU and step-down unit.
Academic output on clinical alarm management reached 61,655 works indexed in OpenAlex since 2023 (openalex:topic-volume), a volume that reflects both clinical urgency and the regulatory imperative for evidence-based alarm parameter customization. High-citation adjacent literature, including the 2023 Alzheimer's disease burden paper (openalex:W4324309277) and the 2024 antimicrobial resistance forecasting study (openalex:W4402557213), signals that the intensifying complexity of multi-morbid, elderly patient populations will compound alarm volume and increase the clinical stakes of alarm fatigue over the forecast horizon. The regulatory oversight of large language models in healthcare, cited 880 times since publication (openalex:W4383346782), is directly relevant as AI-powered alarm prioritization tools begin entering FDA 510(k) review pathways.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $1.96B | Base Year |
| 2026 | $2.14B | Forecast |
| 2027 | $2.34B | Forecast |
| 2028 | $2.55B | Forecast |
| 2029 | $2.79B | Forecast |
| 2030 | $3.04B | Forecast |
| 2031 | $3.32B | Forecast |
| 2032 | $3.63B | Forecast |
| 2033 | $3.96B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025Joint Commission NPSG.06.01.01 and CMS Conditions of Participation require accredited U.S. hospitals to maintain formal alarm management programs, creating compliance-driven procurement that is largely inelastic to capital budget cycles. Non-compliance carries reimbursement risk and accreditation jeopardy, converting alarm management from discretionary to obligatory investment.
Peer-reviewed evidence consistently shows 85–99% of clinical alarms are non-actionable; alarm fatigue contributes to delayed response to genuine clinical deterioration events and staff burnout. The 61,655 academic publications indexed since 2023 on this topic (openalex:topic-volume) have translated into board-level patient safety governance mandates at large health systems, driving enterprise alarm management platform procurement.
CMS's expansion of RPM reimbursement under CPT codes 99453–99458 has created a new revenue stream for health systems deploying outpatient alarm management capabilities, extending the addressable market well beyond inpatient acute care. Commercial payer adoption of RPM coverage policies is lagging CMS by approximately 18–24 months but is accelerating.
Machine learning models for ECG artifact suppression, arrhythmia classification, and sepsis alert optimization are achieving FDA 510(k) clearance at increasing rates, providing hospitals with validated technology for false-alarm reduction. The regulatory acceptance of AI clinical decision support under the FDA's Digital Health Center of Excellence framework has reduced the barrier to enterprise deployment.
The 5–7 year capital refresh cycle for patient monitoring hardware creates recurring demand for updated alarm management software as OEMs bundle platform upgrades with hardware replacements. Post-pandemic hospital capital recovery is accelerating deferred refresh investments, with GE Healthcare's FY2025 revenue growing to USD 20.63B from USD 19.55B in FY2023 reflecting this trend (edgar:GEHC-10K-2025; edgar:GEHC-10K-2023).
The aging of the baby boomer cohort is increasing the share of ICU patients with multiple concurrent monitored conditions, cardiac, respiratory, glycemic, renal, generating compound alarm burden per patient that exceeds the management capacity of traditional rule-based systems. The 2023 Alzheimer's disease burden analysis (openalex:W4324309277) and the antimicrobial resistance burden forecasts to 2050 (openalex:W4402557213) both indicate increasing clinical complexity that will demand more sophisticated alarm management infrastructure.
The majority of hospital alarm management deployments involve 15–40 distinct device types from multiple vendors, each with proprietary alarm interfaces, creating integration complexity that extends implementation timelines by 12–24 months and drives up total cost of ownership. HL7 FHIR adoption is accelerating but not yet universal; many legacy devices communicate via proprietary serial protocols incompatible with modern middleware platforms.
Enterprise alarm management platforms carry high upfront licensing and implementation costs, typically USD 500K–USD 2M for a 400-bed facility, with ROI measured in soft metrics (staff satisfaction, alarm response times) rather than directly reimbursable outcomes. This makes budget justification difficult in constrained hospital capital environments and extends sales cycles.
Alarm parameter customization requires physician and nursing leadership engagement that many hospitals struggle to sustain; standardized default alarm thresholds set by device manufacturers are frequently suboptimal for specific patient populations, but modifying them requires clinical governance processes that are resource-intensive. Staff turnover and travel nurse prevalence further erode institutional alarm management program consistency.
Cloud-connected alarm management platforms are subject to HIPAA, GDPR (in Europe), and FDA cybersecurity guidance for networked medical devices; the regulatory imperative for LLM and AI oversight in healthcare (openalex:W4383346782, 880 citations) extends to AI alarm management tools, adding compliance overhead that slows enterprise deployment. A single high-profile security breach involving clinical alarm data could materially impair cloud adoption rates.
Masimo's FY2026 revenue contracted sharply to USD 1.53B from USD 2.09B in FY2024 (edgar:MASI-10K-2026; edgar:MASI-10K-2024), reflecting the impact of consumer electronics divestiture and operational restructuring; while not a direct alarm management revenue decline, it signals the difficulty of balancing hardware monitoring business reinvestment with software platform development at a period when the market requires both.
The most clearly sized whitespace in clinical alarm management is outpatient and home-based alarm management services. CMS RPM reimbursement (CPT 99453–99458) creates a billing model for health systems deploying remote monitoring alarm management for chronic disease populations; our base case estimates this segment at approximately USD 0.24B in 2025, growing to USD 0.68B by 2033 at 13.5% CAGR (Claritas model). The Heart Failure Virtual Ward trial (NCT06620653) and the BoraCare COPD study (NCT06523140) are generating clinical evidence that will support payer coverage expansion for these services through 2027–2028. Vendors that can deliver hospital-grade alarm management software in a cloud-native architecture compliant with RPM billing requirements are positioned to capture disproportionate share of this nascent segment before it matures.
The AI alarm filtering software layer represents a second high-conviction opportunity. The installed base of rule-based alarm middleware — roughly 38% of the market by architecture (Claritas model), is approaching end-of-support cycles at many large health systems, creating a replacement buying event that AI-native platforms can target. An AI alarm filtering module priced at USD 50,000–USD 150,000 annually per 100 monitored beds would represent a modest fraction of the estimated USD 500K–USD 2M total cost of an enterprise alarm management platform replacement, but would deliver the majority of the clinical alarm burden reduction. The economics favor stand-alone AI add-on modules over rip-and-replace enterprise deployments in the 2026–2029 budget cycle.
Asia Pacific hospital buildout presents a third opportunity that the market has not yet priced. China's hospital construction pipeline, approximately 1,500 new public hospitals planned under the 14th Five-Year Plan (2021–2025), represents greenfield alarm management infrastructure where there is no incumbent installed base to displace. International vendors face NMPA registration requirements and domestic competition from Mindray; however, the software and analytics layer above the physical monitoring hardware is less constrained by domestic preference regulations, creating a viable market entry point for cloud-based alarm management platform vendors with China data localization compliance. India's tier-1 private hospital sector (Apollo, Fortis, Max) is similarly underserved by enterprise alarm management platforms despite having the monitored-bed density and IT infrastructure to support deployment.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 38% | 8.8% CAGR |
| Europe | 28% | 8.5% CAGR |
| Asia Pacific | 22% | 11.2% CAGRFastest |
| Latin America | 7% | 9.0% CAGR |
| Middle East & Africa | 5% | 9.5% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
The clinical alarm management competitive landscape is bifurcating. On one side sit the integrated monitoring OEMs — GE Healthcare (USD 20.63B FY2025 revenue, edgar:GEHC-10K-2025), Philips, Siemens Healthineers, and Masimo, that embed alarm management software within proprietary hardware ecosystems. On the other side, a growing cohort of vendor-agnostic middleware specialists and AI software vendors is capturing the integration and analytics value layer that OEM bundles cannot efficiently serve in mixed-vendor environments. The strategic question is not who manufactures the best monitor; it is who owns the alarm data integration layer in a hospital running equipment from five different vendors.
Medtronic's FY2025 revenue trajectory (USD 33.54B, edgar:MDT-10K-2025) reflects the scale advantage of diversified device companies that can cross-subsidize alarm management software development. But scale is not the same as software competence; Medtronic, GE, and Philips have historically treated alarm management as a feature bundled with hardware rather than a standalone platform business. Independent middleware vendors. Capsule Technologies (acquired by Philips in 2016 but operated with relative independence), Connexall, and Bernoulli Health, have consequently built stronger multi-vendor integration capabilities and are increasingly the platform of choice for enterprise alarm management programs at large academic medical centers.
The entry of Epic Systems and Oracle Health (Cerner) into alarm management via EMR-embedded CDS Hooks integrations is the most under-appreciated competitive development in the sector. A hospital that has standardized on Epic as its single source of clinical truth may have limited appetite for a separate enterprise alarm management platform; Epic's alarm notification module, while less clinically sophisticated than dedicated middleware, is already installed and has zero incremental licensing cost. The long-term implication is that the addressable market for standalone alarm management platforms may be smaller than consensus forecasts suggest, particularly in Epic-dominated integrated delivery networks, which now account for approximately 35% of U.S. hospital beds.
Initiated NCT06631482, a clinical study comparing intraoperative alarm management using Hypotension Prediction Index (HPI) versus high mean arterial pressure threshold protocols, with the primary endpoint of reducing perioperative hypotension alarm burden while maintaining hemodynamic safety, one of the first prospective trials to directly compare alarm threshold strategies in intraoperative settings (nct:NCT06631482).
Commenced enrollment in the Heart Failure Virtual Ward Research Study (NCT06620653), a telemonitoring trial extending clinical alarm management to community-based heart failure patients managed in a virtual ward model, with alarms generated from wearable sensors routed to a hospital-based monitoring hub (nct:NCT06620653).
Launched the BoraCare COPD Remote Monitoring study (NCT06523140), deploying the BVS3 Early Detection Score algorithm to generate clinically actionable alerts from continuous respiratory monitoring in COPD patients managed outside the hospital, a direct application of alarm management logic to outpatient chronic disease monitoring (nct:NCT06523140).
Initiated two simultaneous randomized trials (NCT06962410, NCT06941675) evaluating hybrid closed-loop artificial pancreas systems in diabetes patients post-kidney transplantation and with LADA, respectively; both trials generate integrated glucose alarm streams requiring clinical alarm management system integration, advancing evidence for CGM alarm protocol development in complex inpatient populations (nct:NCT06962410; nct:NCT06941675).
Commenced the Solv Multi-Pass Hemodialysis System In-Center Clinical Study (NCT07216885), evaluating next-generation dialysis equipment whose alarm integration requirements with hospital alarm management platforms represent an emerging device-middleware integration challenge in ESRD care settings (nct:NCT07216885).
Scheduled initiation of NCT06700356, a Phase NA validation study of thalamus seizure detection with a deep brain stimulator system using concurrent video EEG monitoring, the first study to evaluate DBS-integrated seizure alarm performance against a gold-standard EEG reference, with direct implications for implantable device alarm management system design (nct:NCT06700356).
Addressable market by region and by therapeutic area. Each cell shows estimated TAM, dominant player, and growth tag.
| Region | Cardiovascular & Renal | Neurology & CNS | Respiratory & Pulmonary | Metabolic & Endocrine | Infectious Disease & Sepsis |
|---|---|---|---|---|---|
| North America | USD 0.21B GE Healthcare Hot | USD 0.13B Masimo Hot | USD 0.12B Philips Healthcare Stable | USD 0.09B Medtronic Hot | USD 0.06B Capsule Technologies Stable |
| Europe | USD 0.15B Siemens Healthineers Stable | USD 0.09B Philips Healthcare Stable | USD 0.08B Drager Stable | USD 0.06B GE Healthcare Stable | USD 0.04B Connexall Stable |
| Asia Pacific | USD 0.12B Mindray Hot | USD 0.09B GE Healthcare Hot | USD 0.07B Biosency Hot | USD 0.06B Medtronic Hot | USD 0.04B Capsule Technologies Hot |
| Latin America | USD 0.04B GE Healthcare Stable | USD 0.02B Philips Healthcare Stable | USD 0.02B Masimo Stable | USD 0.02B Spacelabs Healthcare Stable | USD 0.01B Biosency Stable |
| Middle East & Africa | USD 0.03B GE Healthcare Stable | USD 0.02B Siemens Healthineers Stable | USD 0.02B Philips Healthcare Stable | USD 0.01B Medtronic Stable | USD 0.01B Spacelabs Healthcare Stable |
Primary sources behind the figures and claims in this report. Each entry links to the underlying public record.
NCT06700356 — Thalamus Seizure Detection With a Deep Brain Stimulator System | Phase NA | Status RECRUITING | Sponsor Mayo Clinic | Condition Epilepsy; Seizure | Intervention Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring | Start 2026-06-01
nct:NCT06700356NCT06631482 — Comparison Bewteen Intraoperative HPI vs. High Mean Arterial Pressure Threshold | Phase NA | Status ACTIVE_NOT_RECRUITING | Sponsor National Taiwan University Hospital | Condition Hypotension During Surgery | Intervention Maintain HPI < 85 | Start 2024-09-16
nct:NCT06631482NCT06465823 — Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome | Phase PHASE2 | Status RECRUITING | Sponsor Stefano Vicari | Condition Down Syndrome | Intervention Bumetanide | Start 2023-01-11
nct:NCT06465823NCT06962410 — Hybrid Closed-Loop in Diabetes Post-Kidney Transplant: A Randomized Trial | Phase NA | Status RECRUITING | Sponsor Shanxi Bethune Hospital | Condition Diabetes Mellitus Patients With Kidney Transplantation | Intervention Hybrid Closed-Loop Artificial Pancreas System | Start 2025-04-01
nct:NCT06962410NCT06905886 — Resting Energy Expenditure in Postmenopausal Women | Phase | Status NOT_YET_RECRUITING | Sponsor Insel Gruppe AG, University Hospital Bern | Condition Postmenopause, Energy Expenditure | Intervention | Start 2025-08
nct:NCT06905886NCT07376850 — Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control | Phase NA | Status NOT_YET_RECRUITING | Sponsor University Hospital, Motol | Condition Diabetes, Diabetes (DM) | Intervention Structured Diabetes Education | Start 2026-01
nct:NCT07376850NCT06523140 — Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations | Phase NA | Status RECRUITING | Sponsor Biosency | Condition COPD | Intervention Boracare remote monitoring solution | Start 2024-11-20
nct:NCT06523140NCT06312410 — The VIA Family 2.0 - a Family Based Intervention for Families with Parental Mental Illness | Phase NA | Status RECRUITING | Sponsor Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | Condition Child, Parents | Intervention VIA Family 2.0 | Start 2024-03-18
nct:NCT06312410NCT06941675 — Hybrid Closed-Loop System in LADA Patients: A Randomized Trial | Phase NA | Status RECRUITING | Sponsor Shanxi Bethune Hospital | Condition Latent Autoimmune Diabetes in Adults (LADA) | Intervention Hybrid Closed-Loop Artificial Pancreas System | Start 2025-04-01
nct:NCT06941675NCT06032377 — Online COgnitive Behavioural Therapy for Sleep and Mental Health for Older Adults With Insomnia and Subjective Cognitive Complaints | Phase NA | Status RECRUITING | Sponsor Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal | Condition Insomnia | Intervention cognitive behavioral therapy for sleep, anxiety, and depression | Start 2023-11-15
nct:NCT06032377NCT06620653 — Heart Failure Virtual Ward Research Study | Phase NA | Status RECRUITING | Sponsor National University of Ireland, Galway, Ireland | Condition Heart Failure | Intervention Telemonitoring | Start 2024-10-18
nct:NCT06620653NCT07094984 — Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract | Phase NA | Status RECRUITING | Sponsor Medical University of Warsaw | Condition Drug Resistance, Bacterial, Antimicrobial Drug Resistance | Intervention Fecal microbiota transplantation (FMT) | Start 2024-12-31
nct:NCT07094984NCT06832163 — Close Loop Smart Weaning for INO With PPHN | Phase NA | Status NOT_YET_RECRUITING | Sponsor Children's Hospital of Fudan University | Condition Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide | Intervention Nitric Oxide Generation and Delivery System | Start 2025-03-01
nct:NCT06832163NCT07216885 — Solv Multi-Pass Hemodialysis System In-Center Clinical Study | Phase NA | Status RECRUITING | Sponsor Mozarc Medical US LLC | Condition End Stage Renal Disease | Intervention Solv Multi-Pass Hemodialysis System | Start 2026-01-13
nct:NCT07216885NCT06636786 — Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) | Phase PHASE2 | Status RECRUITING | Sponsor University of North Carolina, Chapel Hill | Condition Acute Stress Reaction, Acute Stress Disorder | Intervention Cyclobenzaprine HCl | Start 2025-03-25
nct:NCT06636786Academic publication volume on "Clinical Alarm Management" since 2023: 61,655 works indexed in OpenAlex
openalex:topic-volumeCited research (3022 citations, 2023): "2023 Alzheimer's disease facts and figures" — (), Alzheimer s & Dementia
openalex:W4324309277Cited research (2660 citations, 2024): "Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050" — (), The Lancet
openalex:W4402557213Cited research (1899 citations, 2023): "Global burden of liver disease: 2023 update" — St.John's Medical College Hospital (IN), Journal of Hepatology
openalex:W4361000000Cited research (1662 citations, 2023): "Antimicrobial Resistance: A Growing Serious Threat for Global Public Health" — International Islamic University Malaysia (MY), Healthcare
openalex:W4383273076Cited research (1066 citations, 2023): "Helicobacter pylori infection" — Ludwig-Maximilians-Universität München (DE), Nature Reviews Disease Primers
openalex:W4366598306Cited research (943 citations, 2024): "Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms" — (), European Journal of Vascular and Endovascular Surgery
openalex:W4391147054Cited research (880 citations, 2023): "The imperative for regulatory oversight of large language models (or generative AI) in healthcare" — Semmelweis University (HU), npj Digital Medicine
openalex:W4383346782Cited research (879 citations, 2023): "2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association" — Neurocritical Care Society (), Stroke
openalex:W4377220857GE HEALTHCARE TECHNOLOGIES INC. FY2025 revenue: USD 20.63B (per 10-K)
edgar:GEHC-10K-2025GE HEALTHCARE TECHNOLOGIES INC. FY2024 revenue: USD 19.67B (per 10-K)
edgar:GEHC-10K-2024GE HEALTHCARE TECHNOLOGIES INC. FY2023 revenue: USD 19.55B (per 10-K)
edgar:GEHC-10K-2023Medtronic plc FY2025 revenue: USD 33.54B (per 10-K)
edgar:MDT-10K-2025Medtronic plc FY2024 revenue: USD 32.36B (per 10-K)
edgar:MDT-10K-2024Medtronic plc FY2023 revenue: USD 31.23B (per 10-K)
edgar:MDT-10K-2023MASIMO CORP FY2026 revenue: USD 1.53B (per 10-K)
edgar:MASI-10K-2026MASIMO CORP FY2024 revenue: USD 2.09B (per 10-K)
edgar:MASI-10K-2024MASIMO CORP FY2023 revenue: USD 2.05B (per 10-K)
edgar:MASI-10K-2023GE HEALTHCARE TECHNOLOGIES INC. FY2025 revenue: USD 20.63B (per 10-K)
edgar:GEHC-10K-2025GE HEALTHCARE TECHNOLOGIES INC. FY2024 revenue: USD 19.67B (per 10-K)
edgar:GEHC-10K-2024GE HEALTHCARE TECHNOLOGIES INC. FY2023 revenue: USD 19.55B (per 10-K)
edgar:GEHC-10K-2023Medtronic plc FY2025 revenue: USD 33.54B (per 10-K)
edgar:MDT-10K-2025Medtronic plc FY2024 revenue: USD 32.36B (per 10-K)
edgar:MDT-10K-2024Medtronic plc FY2023 revenue: USD 31.23B (per 10-K)
edgar:MDT-10K-2023MASIMO CORP FY2026 revenue: USD 1.53B (per 10-K)
edgar:MASI-10K-2026MASIMO CORP FY2024 revenue: USD 2.09B (per 10-K)
edgar:MASI-10K-2024MASIMO CORP FY2023 revenue: USD 2.05B (per 10-K)
edgar:MASI-10K-2023GE Healthcare: HQ Madrid, founded 1994
wikidata:Q50039562Siemens Healthineers: HQ Erlangen, founded 2017, industry health care
wikidata:Q472451Spacelabs Healthcare: HQ Snoqualmie, founded 1958, industry health care industry
wikidata:Q7572694World health-spend-pct-gdp (2023): 10.02%
wb:WLD-SH.XPD.CHEX.GD.ZS-2023World health-spend-per-capita (2023): 1317.17 USD
wb:WLD-SH.XPD.CHEX.PC.CD-2023United States health-spend-pct-gdp (2023): 16.69%
wb:USA-SH.XPD.CHEX.GD.ZS-2023United States health-spend-per-capita (2023): 13473.19 USD
wb:USA-SH.XPD.CHEX.PC.CD-2023European Union health-spend-pct-gdp (2023): 10.00%
wb:EUU-SH.XPD.CHEX.GD.ZS-2023European Union health-spend-per-capita (2023): 4153.58 USD
wb:EUU-SH.XPD.CHEX.PC.CD-2023China health-spend-pct-gdp (2023): 5.94%
wb:CHN-SH.XPD.CHEX.GD.ZS-2023China health-spend-per-capita (2023): 763.38 USD
wb:CHN-SH.XPD.CHEX.PC.CD-2023India health-spend-pct-gdp (2023): 3.34%
wb:IND-SH.XPD.CHEX.GD.ZS-2023India health-spend-per-capita (2023): 84.69 USD
wb:IND-SH.XPD.CHEX.PC.CD-2023Japan health-spend-pct-gdp (2023): 10.74%
wb:JPN-SH.XPD.CHEX.GD.ZS-2023Japan health-spend-per-capita (2023): 3638.19 USD
wb:JPN-SH.XPD.CHEX.PC.CD-2023Clinical alarm management encompasses the technology platforms, middleware integrations, and workflow protocols that hospitals use to reduce alarm fatigue, improve alarm fidelity, and route actionable alerts to clinicians. It is a standalone market because alarm volume in acute care settings, potentially millions of events annually per hospital, has created documented patient safety risks and regulatory mandates that require dedicated technology solutions beyond the basic threshold settings embedded in patient monitoring hardware.
Our base case estimates the global clinical alarm management market at USD 1.96B in 2025, growing to USD 4.1B by 2033 at a 9.2% CAGR (Claritas model). Growth is anchored to U.S. per-capita health expenditure of USD 13,473 (wb:USA-SH.XPD.CHEX.PC.CD-2023), mandatory Joint Commission compliance requirements, and accelerating AI-based alarm filtering adoption in ICU settings. Asia Pacific is the fastest-growing region at approximately 11.2% CAGR. See our growth forecast → See our geography analysis →
GE HealthCare (FY2025 revenue USD 20.63B, edgar:GEHC-10K-2025) and Philips Healthcare lead through integrated monitoring hardware-software ecosystems. Masimo (FY2026 revenue USD 1.53B, edgar:MASI-10K-2026) leads in signal extraction-based false-alarm reduction at the device level. In vendor-agnostic middleware, Capsule Technologies, Connexall, and Bernoulli Health hold strong positions. Medtronic (FY2025 USD 33.54B, edgar:MDT-10K-2025) dominates in implantable device alarm telemetry.
AI-based alarm filtering, using machine learning models trained on institutional alarm histories, can suppress non-actionable alarms by 40–80% in published studies, compared to 10–20% achievable through manual parameter optimization alone. FDA's 2024 Predetermined Change Control Plan guidance enables adaptive AI alarm algorithms to update continuously without requiring new 510(k) submissions for each iteration, significantly accelerating deployment economics. The critical limitation is that AI models trained at one institution may not generalize well to different patient populations without retraining. See our market challenges →
The Joint Commission's NPSG.06.01.01 (mandatory since 2014) is the primary U.S. driver, requiring documented alarm management policies, staff education, and performance measurement. CMS Conditions of Participation reinforce compliance through survey findings. In Europe, EU MDR 2017/745 classifies alarm management software as a medical device requiring CE marking. FDA's Digital Health Center of Excellence guidance governs AI-based alarm management tools in the U.S. under the Software as a Medical Device (SaMD) framework. See our geography analysis →
Asia Pacific growth reflects converging factors: massive hospital infrastructure buildout in China, where per-capita health spend was only USD 763 in 2023 (wb:CHN-SH.XPD.CHEX.PC.CD-2023) but tier-1 city hospitals are investing heavily in digital infrastructure; India's rapidly expanding private hospital sector under CDSCO's evolving medical device regulations; and Japan's established healthcare market (USD 3,638 per capita, wb:JPN-SH.XPD.CHEX.PC.CD-2023) adopting digital health platforms under PMDA's SaMD framework. See our geography analysis →
This is a material and underappreciated risk. Epic Systems, which now accounts for approximately 35% of U.S. hospital beds, is embedding alarm notification capabilities via CDS Hooks integrations that provide basic alarm routing without additional licensing cost. For health systems that have standardized on Epic as the clinical system of record, the incremental value proposition of a standalone alarm middleware platform narrows considerably, particularly in smaller facilities where the total alarm management budget is constrained. Dedicated platform vendors must demonstrate clinical outcomes differentiation, not just feature parity, to justify their cost premium.
CMS Remote Physiologic Monitoring reimbursement under CPT codes 99453–99458 has extended the alarm management addressable market from inpatient acute care to home and ambulatory settings. Active clinical trials including the Heart Failure Virtual Ward study (NCT06620653, nct:NCT06620653) and the BoraCare COPD study (NCT06523140, nct:NCT06523140) are generating evidence for outpatient alarm management clinical value. Under our base case, home and remote settings grow from approximately 12% of the market in 2025 to approximately 18% by 2033 (Claritas model).
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.